[Proceedings of The National Academy of Sciences of The United States of America] Genetic ablation or pharmacological inhibition of NAT10 restricted the survival and self-renewal of LSCs in primary t(8;21) acute myeloid leukemia (AML) CD34 + cells, as well as in a retroviral AML1-ETO9a-driven t(8;21) AML mouse model.